“Epidemiological Transition”: WHO Declares First Era in History Where Non-Communicable Disease Deaths Triple Infectious Disease Deaths
According to the new Global Health Estimates 2026 report, in 2025, 78% of all deaths worldwide were caused by non-communicable diseases (NCDs), with ischemic heart disease as the leading cause, surpassing the combined death toll from HIV, tuberculosis, and malaria.
We are witnessing not just a statistical milestone, but a moment when the global health system officially acknowledges that the model built on fighting infections is irrevocably outdated. The WHO calls this an “epidemiological transition,” but the reality is harsher—it is not a transition but a fixation of a new world order of mortality, where NCDs account for 78% of all deaths, and ischemic heart disease alone kills more people than HIV, tuberculosis, and malaria combined. This is not merely a change in the ranking of causes of death—it is a declaration of bankruptcy for the entire healthcare architecture built after World War II.
The Essence: What Is Really Happening
Behind the dry phrase “78% of deaths from NCDs” lies a tectonic shift in health economics. The leading cause of death—ischemic heart disease—is not an infection that can be defeated with a vaccine or antibiotic in 10 days. It is the result of decades of accumulated risk factors: hypertension, obesity, smoking, and air pollution. The WHO notes that over 80% of cardiovascular disease deaths are linked to modifiable factors. This means humanity is dying not from incurable diseases, but from living conditions it has created itself.
The Global Health Estimates 2026 report does not just state a fact—it records the failure of global goals. Back in 2015, UN countries committed to reducing premature mortality from NCDs by one-third by 2030 (SDG target 3.4). Ten years later, WHO monitoring shows “uneven progress.” Some countries have achieved success in tobacco control and clinical guidelines for NCDs, but the overall goal remains unmet. Over 100 countries have shown progress on individual indicators since 2022, but it is not enough.
Timeline and Context
The roadmap for this transition has been written over decades, but May 2026 became the point where the curves on the graph finally crossed:
1990. Cardiovascular diseases claimed 13.1 million lives annually. Infections still dominated statistics in developing countries.
2015. Adoption of SDG target 3.4—reducing premature mortality from NCDs by one-third by 2030. At the same time, the WHO published global voluntary targets: a 25% reduction in mortality from four major NCDs by 2025, a 30% reduction in salt consumption, and a 30% reduction in tobacco use prevalence.
2023. CVD deaths reached 19.2 million—an absolute increase of nearly 50% over three decades. Despite a decline in age-standardized mortality in some regions, the total number of deaths is rising due to population aging.
September 2025. The Fourth UN High-Level Meeting on NCDs in New York. The NCD Alliance sounds the alarm: the draft political declaration is “significantly less ambitious” than previous versions, goals are blurring, and language is softening.
May 2026. Global Health Estimates 2026 records: 78% of deaths from NCDs—a new record. Ischemic heart disease surpasses the combined death toll from HIV, tuberculosis, and malaria.
Who Wins and Who Loses
The main beneficiary of this transition is pharmaceutical companies, which have already restructured their portfolios for chronic diseases. Novo Nordisk with Ozempic and Wegovy, Eli Lilly with Mounjaro—their market capitalization reflects not just demand for diabetes and obesity drugs, but a fundamental shift in disease burden. The obesity drug market, estimated at $100 billion by 2030, is a direct consequence of the same epidemiological transition.
The MedTech sector also wins. Chronic NCDs require constant monitoring: glucose meters, cardiac monitors, blood pressure sensors. The wearable medical device market is growing at 25% annually, driven precisely by NCDs.
Infectious disease medicine in its traditional sense loses. Global funds fighting HIV, tuberculosis, and malaria (The Global Fund, PEPFAR) find themselves in a position where their share of total mortality is shrinking, but budgets cannot be instantly redistributed due to political commitments.
The biggest loser is low- and middle-income countries, where NCDs are growing fastest, and healthcare systems are still designed for infections. India bears 20% of the global disease burden but spends only 1% of global health expenditure; NCDs are growing at an annual rate of 2-9%, and first heart attacks and strokes occur 10-15 years earlier than the global average. The economic damage from NCDs to India over a ten-year horizon is estimated at nearly $6 trillion.
What the Media Isn’t Saying
Here is an inside scoop missing from the WHO press release but voiced by experts: the failure of NCD targets is not a medical failure but a political one. The NCD Alliance directly states that the revision of the 2025 UN political declaration leads to “further weakening” of commitments. Language about raising taxes on tobacco, alcohol, and sugary drinks—the most proven measures to reduce NCDs—is being watered down under industry pressure.
The situation in India is a microcosm of the global problem. With NCDs growing at 2-9% per year, 44% of healthcare costs are paid out-of-pocket by patients. This means that a diagnosis of diabetes or hypertension for 430 million Indians in the “missing middle”—those not covered by government programs but unable to afford private insurance—becomes not just a medical problem but a path to financial catastrophe.
A second non-obvious point: the difference between absolute and standardized indicators, which the WHO does not emphasize in headlines. The absolute number of CVD deaths has risen from 13.1 million to 19.2 million. But age-standardized mortality in some regions is declining. This means people are living long enough to die from NCDs rather than infections—and that is a success, not a failure. Yet the WHO presents it as a crisis because the organization operates in a paradigm of “reducing mortality” rather than “managing aging.”
Forecast: Next 30 Days and 90 Days
In the next 30 days, expect G7 countries to issue a joint statement promising to “review” funding for NCD programs. No specific figures will be announced, but the very fact of a response to the WHO report will create short-term positive momentum for stocks of companies in the chronic disease segment.
Simultaneously, the NCD alliance will launch a campaign for including specific tax measures in national strategies. Expect open letters demanding higher excise taxes on sugary drinks and tobacco—and government silence in response.
Within a 90-day horizon, a deeper shift will occur: the World Bank and IMF will begin incorporating the NCD burden into their country reports as a macroeconomic risk factor. This is not just statistics—it will change lending conditions for developing countries. If a country does not invest in NCD prevention, its sovereign credit rating may be downgraded due to future healthcare costs. The first to be hit will be India, Indonesia, and Nigeria—countries with the largest absolute NCD burden and the least fiscal capacity to respond.
The epidemiological transition is complete not in the sense that infections are defeated, but in that humanity has crossed a threshold where the main enemy is not a microbe but a lifestyle. We have entered an era where ischemic heart disease kills more people than the three major infectious killers combined, and this is not a triumph of medicine but a verdict on a healthcare system still preparing for the last war.
— Editorial Team
